ClearPoint Neuro, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $37.0M | $31.4M | $24.0M | $20.6M | $16.3M |
| Cost of revenue | $14.3M | $12.3M | $10.3M | $7.0M | $5.2M |
| Gross profit | $22.7M | $19.1M | $13.6M | $13.5M | $11.1M |
| Selling, general & administrative | $16.5M | $12.0M | $11.8M | $9.6M | $8.0M |
| Research and development | $13.9M | $12.4M | $11.7M | $10.9M | $9.3M |
| Operating income | -$24.2M | -$19.7M | -$22.4M | -$16.3M | -$13.4M |
| Interest expense | $2.4M | $518,000 | — | $81,000 | $973,000 |
| Pretax income | -$25.5M | -$18.9M | — | — | — |
| Income tax expense | $55,000 | $12,000 | $8,000 | $0 | $0 |
| Net income | -$25.5M | -$18.9M | -$22.1M | -$16.4M | -$14.4M |
| Balance Sheet | |||||
| Cash and equivalents | $45.9M | $20.1M | $23.1M | $27.6M | $54.1M |
| Current assets | $63.6M | $33.4M | $36.2M | $51.2M | $61.9M |
| Total assets | $97.7M | $39.2M | $42.7M | $55.5M | $65.6M |
| Current liabilities | $10.8M | $10.4M | $7.4M | $6.8M | $4.8M |
| Total liabilities | $69.7M | $13.8M | $21.5M | $18.6M | $16.8M |
| Total debt | $50.9M | — | $10.0M | $10.0M | $10.0M |
| Stockholders' equity | $28.0M | $25.4M | $21.2M | $36.9M | $48.8M |
| Cash Flow Statement | |||||
| Cash from operations | -$23.9M | -$8.9M | -$13.7M | -$16.2M | -$12.7M |
| Depreciation and amortization | $814,000 | $980,000 | $626,000 | $244,000 | $159,000 |
| Stock-based compensation | $8.2M | $6.9M | $6.1M | $4.1M | $2.1M |
| Capital expenditure | $522,000 | $275,000 | $717,000 | $253,000 | $168,000 |
| Free cash flow | -$24.4M | -$9.2M | -$14.4M | -$16.4M | -$12.9M |
Shares outstanding 30.0M · Free float 38.1%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.